Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXS NASDAQ:EVAX NASDAQ:LIMN NASDAQ:PLUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.60$0.60$0.00▼$0.80$35.79M1.7515,632 shsN/AEVAXEvaxion A/S$3.92-4.9%$3.99$1.62▼$12.15$34.36M0.2636,328 shs26,211 shsLIMNLiminatus Pharma$0.18-2.2%$0.20$0.16▼$33.66$8.26MN/A1.01 million shs754,434 shsPLURPluri$3.37-0.9%$3.35$2.82▼$5.96$36.64M0.756,876 shs7,999 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%0.00%0.00%0.00%+1,911.83%EVAXEvaxion A/S-4.85%-9.68%-5.31%+17.37%+139.02%LIMNLiminatus Pharma-2.17%-11.24%-3.02%-52.13%+17,999,900.00%PLURPluri-0.88%-3.16%-2.60%-7.80%-30.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.60$0.60$0.00▼$0.80$35.79M1.7515,632 shsN/AEVAXEvaxion A/S$3.92-4.9%$3.99$1.62▼$12.15$34.36M0.2636,328 shs26,211 shsLIMNLiminatus Pharma$0.18-2.2%$0.20$0.16▼$33.66$8.26MN/A1.01 million shs754,434 shsPLURPluri$3.37-0.9%$3.35$2.82▼$5.96$36.64M0.756,876 shs7,999 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%0.00%0.00%0.00%+1,911.83%EVAXEvaxion A/S-4.85%-9.68%-5.31%+17.37%+139.02%LIMNLiminatus Pharma-2.17%-11.24%-3.02%-52.13%+17,999,900.00%PLURPluri-0.88%-3.16%-2.60%-7.80%-30.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/AEVAXEvaxion A/S 2.67Moderate Buy$11.00180.61% UpsideLIMNLiminatus Pharma 1.00SellN/AN/APLURPluri 2.00Hold$12.00256.08% UpsideCurrent Analyst Ratings BreakdownLatest LIMN, EVAX, ADXS, and PLUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026EVAXEvaxion A/S HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.003/27/2026LIMNLiminatus Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/10/2026EVAXEvaxion A/S JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.003/9/2026EVAXEvaxion A/S Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$11.00 ➝ $9.003/9/2026EVAXEvaxion A/S HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.002/19/2026EVAXEvaxion A/S Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 5/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M11.05N/AN/A($2.06) per share-0.29EVAXEvaxion A/S$7.53M4.34N/AN/A$1.58 per share2.48LIMNLiminatus PharmaN/AN/AN/AN/A($0.36) per shareN/APLURPluri$1.34M27.12N/AN/A($0.11) per share-30.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$5.02N/AN/AN/AN/AN/AN/AN/AEVAXEvaxion A/S-$7.71M-$1.47N/A0.71N/AN/A-73.56%-37.45%N/ALIMNLiminatus Pharma-$10.21M-$0.15N/AN/AN/AN/AN/A-402.52%N/APLURPluri-$22.58M-$4.53N/AN/AN/A-2,162.08%N/A-100.18%N/ALatest LIMN, EVAX, ADXS, and PLUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026LIMNLiminatus PharmaN/A-$0.03N/A-$0.03N/AN/A5/14/2026Q3 2026PLURPluri-$0.66-$0.55+$0.11-$0.55$0.66 million$0.17 million5/7/2026Q1 2026EVAXEvaxion A/S-$0.01-$0.44-$0.43-$0.10$9.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AEVAXEvaxion A/SN/AN/AN/AN/AN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/AEVAXEvaxion A/S0.415.855.85LIMNLiminatus PharmaN/A0.050.05PLURPluriN/A0.430.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%EVAXEvaxion A/S11.04%LIMNLiminatus PharmaN/APLURPluri16.59%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%EVAXEvaxion A/S41.64%LIMNLiminatus PharmaN/APLURPluri25.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2059.31 million42.36 millionNot OptionableEVAXEvaxion A/S608.34 million4.87 millionNo DataLIMNLiminatus PharmaN/A44.88 millionN/AN/APLURPluri15010.78 million7.98 millionNo DataLIMN, EVAX, ADXS, and PLUR HeadlinesRecent News About These CompaniesPluri (PLUR) Projected to Post Quarterly Earnings on ThursdayMay 6, 2026 | americanbankingnews.comNewcelX and Eledon Pharmaceuticals Collaborate on NCEL-101 for Type 1 Diabetes, Reporting Strong Financial Position and Strategic Growth PlansApril 30, 2026 | quiverquant.comQPluri Announces Financing Through Unregistered Equity Securities DealMarch 27, 2026 | tipranks.comPluri Inc.: Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private PlacementMarch 26, 2026 | finanznachrichten.dePluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private PlacementMarch 26, 2026 | finance.yahoo.comPluri Regains Nasdaq Compliance, Restoring Listing StabilityMarch 2, 2026 | tipranks.comPluri Biotech Secures China Patent for Immune Cell TechFebruary 18, 2026 | contractpharma.comCPluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. PatentFebruary 18, 2026 | markets.businessinsider.comPluri's cell therapy to extends lifespan and combat chronic diseaseFebruary 17, 2026 | i24news.tvIPluri showcases cell expansion platform as Resbiomed program advancesFebruary 10, 2026 | finance.yahoo.comPluri's Alejandro Weinstein on the future of cell-based technologyFebruary 2, 2026 | msn.comPluri Faces Nasdaq Noncompliance Notice, Evaluating Listing OptionsJanuary 22, 2026 | tipranks.comPluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich BiomaterialsJanuary 22, 2026 | markets.businessinsider.comPluri, Inc. Completes First Phase of Regenerative Medicine Collaboration with Resbiomed TechnologiesJanuary 22, 2026 | quiverquant.comQPluri announces expansion of manufacturing agreement with Remedy CellDecember 22, 2025 | msn.comPluri, Inc. Expands Manufacturing Agreement with Remedy Cell Ltd. for Clinical Development of Cell-Free TherapeuticsDecember 22, 2025 | quiverquant.comQPluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing AchievedDecember 22, 2025 | globenewswire.comA US$3.4m Market Cap Boost Pleasing ToPluri InsidersDecember 19, 2025 | finance.yahoo.comPluri appoints Weinstein as chairman of the board of directorsDecember 10, 2025 | msn.comPluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional InvestmentDecember 9, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLIMN, EVAX, ADXS, and PLUR Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.60 0.00 (0.00%) As of 05/15/2026Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Evaxion A/S NASDAQ:EVAX$3.92 -0.20 (-4.85%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$3.97 +0.05 (+1.28%) As of 05/15/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Liminatus Pharma NASDAQ:LIMN$0.18 0.00 (-2.17%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.18 +0.00 (+2.22%) As of 05/15/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.Pluri NASDAQ:PLUR$3.37 -0.03 (-0.88%) Closing price 05/15/2026 03:59 PM EasternExtended Trading$3.23 -0.14 (-4.12%) As of 05/15/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
